Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.
Also called NCT03029208
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 312 participants
- Sponsor
- Registry
-
NCT03029208 -
2016-000507-86
-
- Other papers using this trial's data
- Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Canada, Germany, India, Italy, Malaysia, Mexico, Poland, Russia, South Africa, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03029208. Randomized; no masking; primary purpose treatment. Start 2017-05-11 (actual); primary completion 2020-09-24 (actual). Results posted on 2021-10-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)
- Condition
- Anaemia
- Intervention (Drug)
- Daprodustat
- Intervention (Drug)
- Darbepoetin alfa
- Intervention (Drug)
- Iron therapy
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct03029208- Content hash
5e4773cf6c314f5f3ecf13cf3fcfca4370f07e416807fb4633ff755dd8a412f7